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Background: Adoptive transfer of tumor directed T cells may
offer an alternative therapy for patients with advance stage solid
tumors as they can expand in vivo, actively migrate through tissue
planes, and use direct and indirect cytotoxic mechanisms to kill
tumor cells. Two major limitations to clinical efficacy are the abil-
ity of many tumors to downregulate MHC expression and de-
crease susceptibility to antigen-specific T cell killing, and the
lack of co-stimulatory molecules on tumor cells leading to incom-
plete T cell activation and poor survival. We attempted to over-
come these limitations by generating an MHC-independent
chimeric antigen receptor (CAR) targeting GD2, a tumor antigen
expressed on almost neuroblastoma cells. We transduced activated
T cells (ATC), and Epstein Barr virus-specific cytotoxic T lym-
phocytes (EBV-CTL) with a distinguishable GD2-CAR and in-
fused them into patients with high-risk neuroblastoma. We
compared the survival of EBV-CTL to ATC expressing the
GD2-CAR and anticipated superior persistence of GD2 EBV-
CTL due to in vivo co-stimulation received following engagement
of their native antigen receptor by chronically expressed EBV an-
tigens in seropositive individuals.
Study Design: The primary objective of this Phase I trial was
to determine safety of escalating doses of GD2-ATC and GD2-
CTL in high-risk neuroblastoma patients. A secondary objective
was to compare the in vivo survival of GD2-ATC versus GD2-
CTL.
Results: Fourteen patients with high-risk neuroblastoma re-
ceived autologous ATC and EBV-CTL transduced with GD2
CARs. No dose limiting toxicities were identified. Of 12 currently
evaluable patients, there was a.10-fold higher mean area under the
curve (number x duration in weeks) of GD2-CTL than GD2-ATC
in peripheral blood. 3 subjects had no evidence of disease at the time
of infusion: one remains disease free .17 months post infusion; 2
are alive with disease at 13 and 34 months. Of the 9 with re-
lapsed/resistant disease, 3 had stable disease for 10 to 16 months
post-infusion, 2 developed tumor inflammation and necrosis, 1
had clearance of marrow disease at 6 weeks, and 1 has a complete
response sustained for .24 months.
Conclusion: Treatment of high-risk neuroblastoma with adop-
tively transferred T cells expressing GD2 CARs appears safe and
can be associated with anti-tumor activity. CAR-CTL may have
a survival advantage over CAR-ATC due to the co-stimulation
received during native receptor engagement by viral antigens.
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Pediatric pts with metastatic or recurrent solid tumors often
relapse even when remissions are consolidated with high dose
chemotherapy and autologous hematopoietic cell transplant
(HCT). We previously showed dendritic cell (DC) based tumor
vaccines to be safe and produce anti-tumor responses in children
with refractory solid tumors. Experimental evidence indicates that
the period of lymphopenia that occurs after HCT may be an op-
portune time to improve the immune response to self tumor.
Furthermore, a DC based tumor vaccine may be most effective
when residual disease burden is minimal, as in the period imme-
diately after HCT. We are testing this hypothesis in an ongoing
clinical trial of tumor-lysate pulsed DC vaccination shortly after
HCT for high-risk pediatric solid tumor pts. Ten pts (median
15y, range 2–21y) have been treated to date. All patients had
metastatic tumors (high grade sarcoma-6, neuroblastoma-3,
Wilms-1), 6 pts had recurrent disease. Autologous tumor col-
lected at time of diagnostic or therapeutic surgery and mononu-
clear cells collected at stem cell harvest for HCT were
cryopreserved for later vaccine generation. Vaccines were gener-
ated by pulsing tumor lysate and keyhole limpet hemocyanin
(KLH) as an immunoadjuvant onto immature DC for 4h fol-
lowed by addition of a maturation cocktail of IL6, IL1b,
PGE2, and TNFa for 18h. Patients in partial remission or better
underwent high-dose alkylator based autologous HCT. Intrader-
mal DC vaccines given every two weeks for a total of 3 vaccines
began at a median of 20d, (range 14–36d), soon after the abso-
lute lymphocyte count reached 200/ml. There have been no vac-
cine associated toxicities or development of autoimmune disease.
Prior to HCT and 2 weeks after the 3rd vaccine, immune test-
ing, including antigen specific T-cell detection by IFNg elispot
assay, was performed. A 3-fold increase in the numbers of
IFNg-secreting T cells was considered a positive result. Positive
responses were observed to KLH in 9/10 pts (median increase
20, range 0.9–351) and to tumor lysate in 6/10 pts (median
increase 6, range 0.1–21). Median follow-up is 12 months.
2/6 pts with response to tumor have relapsed, 3/4 pts without re-
sponse have relapsed. Immunologic and clinical responses are
shown in the table. These preliminary results indicate that
a DC-based vaccination strategy initiated during the early post-
HCT lymphopenic period can generate strong anti-KLH and tu-
mor lysate responses.
Immunologic and Clinical Responses
Patient
Age
(years)
Pre-HCT
status
KLH
response
Tumor
lysate
response
Status
@ 2m
post-HCT
PFS
(months)
Neuroblastoma 3 PR (MIBG
avid abdominal
mass)
1 11 CR 101
Recurrent
Neuroblastoma
3 CR 111 11 CR 12
Recurrent
Neuroblastoma
17 PR (MIBG
avid mediastinal
mass)
11 - SD 3
Synovial sarcoma 17 PR (lung
mets)
- 111 CR 71
Malignant
peripheral
nerve
sheath tumor
10 CR 111 111 CR 121
Recurrent
Osteosarcoma
19 PR (lung
mets)
111 1 SD 3
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Patient
Age
(years)
Pre-HCT
status
KLH
response
Tumor
lysate
response
Status
@ 2m
post-HCT
PFS
(months)
Recurrent
Ewing’s sarcoma
17 PR (pelvic
mass)
111 - SD 3.5
Rhabdoid tumor
of the abdomen
2 CR 111 - CR 3
Recurrent
Chondroblastic
sarcoma
21 PR (lung and
spinal mets)
1 1 SD 151
Recurrent Wilm’s
tumor
13 PR (lung
mets)
1 - CR 71
If\3 baseline, -. If .3 baseline, strength of response based on eli-
spot number: KLH\5001, 500-100011,.1000111; tumor lysate
\100 1, 100-200 11, .200 111.
